Protocol Ledger

NCT05327530 · Phase II · ACTIVE NOT RECRUITING

A Study of the Safety and Efficacy of Various Combinations of Avelumab as Therapy in Locally Advanced or Metastatic Urothelial Carcinoma (JAVELIN Bladder Medley)

Interventional Phase II clinical trial protocol NCT05327530 sponsored by EMD Serono / Merck KGaA in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2022-08-17 Enrollment: 256 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT05327530
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)256 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)3 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05327530
Protocol FieldVerified Registry Value
NCT IdentifierNCT05327530
Consolidated Lead SponsorEMD Serono / Merck KGaA
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment256 participants (ACTUAL)
Registered Start Date2022-08-17
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT05327530
Hospital Research SiteLocationSite Profile
Johns Hopkins Hospital and Kimmel Cancer CenterBaltimore, MDOpen Hospital Dossier ->
Fred Hutchinson Cancer Center and UW MedicineSeattle, WAOpen Hospital Dossier ->
Flinders Medical CentreBedford Park, AustraliaOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI